Ipca Laboratories Limited - Balance (Quarterly)

Ipca Laboratories Limited
IN ˙ NSEI ˙ INE571A01020
1.558,15 ₹ ↑35,20 (2,31%)
2026-04-24
DEL PRIS
Balance (Quarterly)

Ipca Laboratories Limited Balance viser kontosaldi for virksomheden på tidspunkter. Balancedata inkluderer aktiver, omsætningsaktiver, anlægsaktiver, materielle anlægsaktiver (PPE), inventar, immaterielle aktiver, passiver, kortfristede forpligtelser, gæld, kapitalleasingforpligtelser, almindelige aktier, overført overskud, egne aktier og egenkapital.

Alle tal er gange 1,000,000.00 undtagen pr. andel enheder.

2021
09-30
2022
03-31
2022
09-30
2023
03-31
2023
09-30
2024
03-31
2024
09-30
2025
03-31
2025
09-30
Kontanter 5.366 2.752 11.922 12.578 4.988 2.968 2.970 1.672 2.638
Ændring (%) -48,72 333,23 5,51 -60,35 -40,49 0,07 -43,72 57,80
Aktiver Nuværende 39.613 44.572 45.544 51.893 57.196 55.389 56.807 62.685 65.159
Ændring (%) 12,52 2,18 13,94 10,22 -3,16 2,56 10,35 3,95
Aktiver 68.343 76.235 78.982 86.264 113.838 111.013 114.238 117.606 122.627
Ændring (%) 11,55 3,60 9,22 31,96 -2,48 2,90 2,95 4,27
Forpligtelser 14.971 20.818 20.390 27.111 38.230 33.743 33.061 33.723 33.968
Ændring (%) 39,06 -2,05 32,96 41,01 -11,74 -2,02 2,00 0,73
Egenkapital 53.372 55.418 58.591 59.153 75.608 77.270 81.177 83.883 88.658
Ændring (%) 3,83 5,73 0,96 27,82 2,20 5,06 3,33 5,69
Passiver og Aktiekapital 68.343 76.235 78.982 86.264 113.838 111.013 114.238 117.606 122.627
Ændring (%) 11,55 3,60 9,22 31,96 -2,48 2,90 2,95 4,27

Source: Capital IQ

Other Listings
IN:524494 1.558,15 ₹
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista